Latest research on Humira

Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.

Humira indications

Humira is very effective, with more than two-thirds of the patients in clinical trials experiencing a 75% reduction in psoriasis severity (PASI 75) after 16 weeks of treatment, including about 40% of patients who achieved a 90% reduction in psoriasis severity. [source, 2009]
Present basic science experiment is designed to demonstrate the effects of a potential pharmacological agent-adalimumab (Humira, Abbott, Abbott Park, IL, USA)-on SCI in rats. [source, 2015]
Interestingly, anti-TNF (Humira) in the current study was used (as combination) only with MTX (19 times), as bi-therapy (60), as tri-therapy (30), or as tetra-therapy (10); this was in concordance with a previous report that a better effect can be obtained by a combination of MTX with anti-TNF than for MTX alone.14 [source, 2015]
To evaluate the effect of Adalimumab, each rd10 mouse received one intraperitoneal injection of Adalimumab (Humira, Abbot Laboratories) saline solution at 3 mg/kg every three days starting at P9 and until P17. [source, 2015]
RV1088 and Humira also reduced IL-6 production effectively (IC50 = 1.66 nM and IC50 = 0.00172 nM respectively). [source, 2015]
Humira was the most effective overall (IC50 = 0.06 nM). [source, 2015]
Neither Humira nor tofacitinib had any effect on IL-6 or IL-8 synthesis by RA synovial fibroblasts (Supporting Information Fig. S3, Table 1). [source, 2015]
Interestingly, the SKIs, as well as Humira, exhibited a cell type-specific effect, demonstrating good inhibition of some, but not all, cytokines in distinct cell types. [source, 2015]
Increasing concentrations of RV1088, SKIs and Humira were assessed for their effect on endogenous TNF-α, IL-6 and IL-8 production by RA synovial membrane cells. [source, 2015]
Humira was very effective at inhibiting TNF-α synthesis (IC50 = 0.04 nM), but had no effect on IL-6 or IL-8 production by RA synovial membrane cells. [source, 2015]